RT Journal Article
SR Electronic
T1 The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.22.21253655
DO 10.1101/2021.03.22.21253655
A1 Edilova, Maria I.
A1 Law, Jaclyn C.
A1 Zangiabadi, Safoura
A1 Ting, Kenneth
A1 Mbanwi, Achire N.
A1 Arruda, Andrea
A1 Uehling, David
A1 Isaac, Methvin
A1 Prakesch, Michael
A1 Al-awar, Rima
A1 Minden, Mark D.
A1 Abdul-Sater, Ali A.
A1 Watts, Tania H.
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.22.21253655.abstract
AB TRAF1 is a pro-survival adaptor molecule in TNFR superfamily (TNFRSF) signaling. TRAF1 is overexpressed in many B cell cancers including refractory chronic lymphocytic leukemia (CLL). Little has been done to assess the role of TRAF1 in human cancer. Here we show that the protein kinase C related kinase Protein Kinase N1 (PKN1) is required to protect TRAF1 from cIAP-mediated degradation during constitutive CD40 signaling in lymphoma. We show that the active phospho-Thr774 form of PKN1 is constitutively expressed in CLL but minimally detected in unstimulated healthy donor B cells. Through a screen of 700 kinase inhibitors, we identified two inhibitors, OTSSP167 and XL-228, that inhibited PKN1 in the nanomolar range and induced dose-dependent loss of TRAF1 in RAJI cells. OTSSP167 and XL-228 treatment of primary patient CLL samples led to a reduction in TRAF1, pNF-κB p65, pS6, pERK, Mcl-1 and Bcl-2 proteins, and induction of activated caspase-3. OTSSP167 synergized with venetoclax in inducing CLL death, correlating with loss of TRAF1, Mcl-1 and Bcl-2. Although correlative, these findings suggest the PKN1-TRAF1 signaling axis as a potential new target for CLL. These findings also suggest OTSSP167 and venetoclax as a combination treatment for TRAF1 high CLL.Competing Interest StatementMIE, AAS and THW have filed intellectual property on PKN1 inhibition. Funding StatementThis research was funded by a Foundation grant from the Canadian Institute of Health Research (FDN-143250) and an Innovation grant from the Canadian Cancer Society Research Institute (2012-701326) to T.H.W.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent for tissue bank donation was in compliance with the Declaration of Helsinki and in agreement with the UHN Research Ethics Review Board (protocol 01-0573) and the research herein was also approved by the University of Toronto Research Ethics board (Protocol #: 00030910).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDrug titration data are included in supplementary tables. Flow cytometry FCS files are available from the authors upon request.